Regulation of herpes simplex virus 1 replication using tumor-associated promoters

Annals of Surgery

Volumn 236, Issue 4, 2002, Pages 502-513

  Mullen, John T ^a   Kasuya, Hideki ^a   Yoon, Sam S ^a   Carroll, Nancy M ^a   Pawlik, Timothy M ^a   Chandrasekhar, Soundararajalu ^a   Nakamura, Hideo ^a   Donahue, James M ^a   Tanabe, Kenneth K ^a   Fraker, Douglas L ^a   Alexander, Richard ^a   Allison, David C ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; MUCIN 1; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; CANCER THERAPY; CONFERENCE PAPER; CONTROLLED STUDY; CYTOTOXICITY TEST; GENE CONTROL; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; MOLECULAR CLONING; MOUSE; NONHUMAN; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROMOTER REGION; QUANTITATIVE ASSAY; TUMOR XENOGRAFT; VIRUS EXPRESSION; VIRUS MUTANT; VIRUS REPLICATION;

ANIMALS; ANTIGENS, NEOPLASM; CARCINOEMBRYONIC ANTIGEN; CARCINOMA; CERCOPITHECUS AETHIOPS; COLONIC NEOPLASMS; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION, VIRAL; HAPLORHINI; HERPESVIRUS 1, HUMAN; HUMANS; KIDNEY; PROMOTER REGIONS (GENETICS); VIRUS REPLICATION;

EID: 0036785902     PISSN: 00034932     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000658-200210000-00013     Document Type: Conference Paper

References (35)

1. Rosenberg SA, Blaese RM, Brenner MK, et al. Human gene marker/therapy clinical protocols. Hum Gene Ther 2000; 11:919-979.
2. Martuza RL. Conditionally replicating herpes vectors for cancer therapy. J Clin Invest 2000; 105:841-846.
3. Nakamura H, Mullen JT, Chandrasekhar S, et al. Multimodality therapy with a replication-conditional herpes simplex virus 1 mutant that expresses yeast cytosine deaminase for intratumoral conversion of 5-fluorocytosine to 5-fluorouracil. Cancer Res 2001; 61:5447-5452.
4. Ichikawa T, Chiocca EA. Comparative analyses of transgene delivery and expression in tumors inoculated with a replication-conditional or -defective viral vector. Cancer Res 2001; 61:5336-5339.
5. Kooby DA, Carew JF, Halterman MW, et al. Oncolytic viral therapy for human colorectal cancer and liver metastases using a multi-mutated herpes simplex virus type-1 (G207). FASEB J 1999; 13:1325-1334.
6. Puhlmann M, Grant M, Brown CK, et al. Thymidine kinase-deleted vaccinia virus expressing purine nucleoside phosphorylase as a vector for tumor-directed gene therapy. Hum Gene Ther 1999; 10:649-657.
7. Sinkovics JG, Horvath JC. Newcastle disease virus (NDV): brief history of its oncolytic strain. J Clin Virol 2000; 16:1-15.
8. Bischoff JR, Kirn DH, Williams A, et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996; 274:373-376.
9. Coffey MC, Strong JE, Forsyth PA, et al. Reovirus therapy of tumors with activated ras pathway. Science 1998; 282:1332-1334.
10. Carroll NM, Chiocca EA, Takahashi K, et al. Enhancement of gene therapy specificity for diffuse colon carcinoma liver metastases with recombinant herpes simplex virus. Ann Surg 1996; 224:323-330.
11. Yoon SS, Carroll NM, Chiocca EA, et al. Cancer gene therapy using replication-competent herpes simplex virus type 1. Ann Surg 1998; 228:366-374.
12. Goldstein DJ, Weller SK. Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: isolation and characterization of an ICP6 lacZ insertion mutant. J Virol 1988; 62:196-205.
13. Yoon SS, Nakamura H, Carroll NM, et al. An oncolytic herpes simplex virus type 1 selectively destroys diffuse liver metastases from colon carcinoma. FASEB J 2000; 14:301-311.
14. 1 34:5: expression and oncolysis of diffuse liver metastases by Myb34.5. J Clin Invest 2002; 109:871-882.
15. Deluca NA, McCarthy AM, Schaffer PA. Isolation and characterization of deletion mutants of herpes simplex virus type 1 in the gene encoding immediate-early regulatory protein ICP4. J Virol 1985; 56: 558-570.
16. Chou J, Roizman B. The gamma 1(34.5) gene of herpes simplex virus 1 precludes neuroblastoma cells from triggering total shutoff of protein synthesis characteristic of programed cell death in neuronal cells. Proc Natl Acad Sci USA 1992; 89:3266-3270.
17. He B, Gross M, Roizman B. The gamma(1)34.5 protein of herpes simplex virus 1 complexes with protein phosphatase 1 alpha to dephosphorylate the alpha subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-activated protein kinase. Proc Natl Acad Sci USA 1997; 94:843-848.
18. Chung RY, Saeki Y, Chiocca EA. B-myb promoter retargeting of herpes simplex virus gamma 34.5 gene-mediate virulence toward tumor and cycling cells. J Virol 1999; 73:7556-7564.
19. Lelie PN, Reesink HW, Lucas CJ. Inactivation of 12 viruses by heating steps applied during manufacture of a hepatitis B vaccine. J Med Virol 1987; 23:297-301.
20. Richards CA, Austin EA, Huber BE. Transcriptional regulatory sequences of carcinoembryonic antigen: identification and use with cytosine deaminase for tumor-specific gene therapy. Hum Gene Ther 1995; 6:881-893.
21. Abe M, Kufe D. Characterization of cis-acting elements regulating transcription of the human DF3 breast carcinoma-associated antigen (MUC1) gene. Proc Natl Acad Sci USA 1993; 90:282-286.
22. Kurihara T, Brough DE, Kovesdi I, et al. Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUCI antigen. J Clin Invest 2000; 106:763-771.
23. Jain RK. Delivery of molecular medicine to solid tumors. Science 1996; 271:1079-1080.
24. Marshall E. Clinical trials: gene therapy death prompts review of adenovirus vector. Science 1999; 286:2244-2245.
25. Pawlik TM, Nakamura H, Yoon SS, et al. Oncolysis of diffuse hepatocellular carcinoma by intravascular administration of a replication-competent, genetically engineered herpesvirus. Cancer Res 2000; 60: 2790-2795.
26. Becker TM, Lee F, Daling JR, et al. Seroprevalence of and risk factors for antibodies to herpes simplex viruses, hepatitis B, and hepatitis C among southwestern Hispanic and non-Hispanic white women. Sex Transm Dis 1996; 23:138-144.
27. Miyatake S, Iyer A, Martuza RL, et al. Transcriptional targeting of herpes simplex virus for cell-specific replication. J Virol 1997; 71: 5124-5132.
28. Kufe D, Inghirami G, Abe M, et al. Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors. Hybridoma 1984; 3:223-232.
29. Abe M, Kufe D. Transcriptional regulation of DF3 gene expression in human MCF-7 breast carcinoma cells. J Cell Physiol 1990; 143:226-231.
30. Metzgar RS, Rodriguez N, Finn OJ, et al. Detection of a pancreatic cancer-associated antigen (DU-PAN-2 antigen) in serum and ascites of patients with adenocarcinoma. Proc Natl Acad Sci USA 1984; 81:5242-5246.
31. Jarrard JA, Linnoila RI, Lee H, et al. MUC1 is a novel marker for the type II pneumocyte lineage during lung carcinogenesis. Cancer Res 1998; 58:5582-5589.
32. Friedman EL, Hayes DF, Kufe DW. Reactivity of monoclonal anti-body DF3 with a high molecular weight antigen expressed in human ovarian carcinomas. Cancer Res 1986; 46:5189-5194.
33. Meignier B, Martin B, Whitley RJ, et al. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020. II. Studies in immunocompetent and immunosuppressed owl monkeys (Aotus trivirgatus). J Infect Dis 1990; 162:313-321.
34. Goldstein DJ, Weller SK. Factor(s) present in herpes simplex virus type 1 infected cells can compensate for the loss of the large unit of the viral ribonucleotide reductase: characterization of an ICP6 deletion mutant. Virology 1988; 166:41-51.
35. Kramm CM, Chase M, Herrlinger U, et al. Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy. Hum Gene Ther 1997; 8:2057-2068.